Big firms showcase promising pipeline assets at ASCO 2023

As the final sessions of the 2023 congress of the American Society of Clinical Oncology (ASCO) draw to a close, attendees will reflect on a number of significant presentations, from both smaller biotechs and large drugmakers.

One closely-watched area of research is TIGIT inhibition, with Gilead Sciences (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS)  updating the congress on progress from its ARC-7 study of TIGIT blocker domvanalimab, together with the checkpoint blocker zimberelimab.

While the interim analysis in that presentation failed to show a significant improvement from an earlier update, Roche’s (ROG: SIX) TIGIT blocker tiragolumab appears to hold more promise.